These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 27858991)

  • 1. Management of central nervous system involvement in chronic lymphocytic leukaemia: a retrospective cohort of 30 patients.
    Wanquet A; Birsen R; Bonnet C; Boubaya M; Choquet S; Dupuis J; Lepretre S; Re D; Fahri J; Michallet AS; Ysebaert L; Lemal R; Lamy T; Delarue R; Troussard X; Cymbalista F; Levy V; Dietrich PY; Leblond V; Aurran-Schleinitz T
    Br J Haematol; 2017 Jan; 176(1):37-49. PubMed ID: 27858991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of real-world treatment patterns in chronic lymphocytic leukemia management before and after availability of ibrutinib in the province of British Columbia, Canada.
    Huang SJ; Gerrie AS; Young S; Tucker T; Bruyere H; Hrynchak M; Galbraith P; Al Tourah AJ; Dueck G; Noble MC; Ramadan KM; Tsang P; Hardy E; Sehn L; Toze CL
    Leuk Res; 2020 Apr; 91():106335. PubMed ID: 32114372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.
    Michallet AS; Dilhuydy MS; Subtil F; Rouille V; Mahe B; Laribi K; Villemagne B; Salles G; Tournilhac O; Delmer A; Portois C; Pegourie B; Leblond V; Tomowiak C; de Guibert S; Orsini F; Banos A; Carassou P; Cartron G; Fornecker LM; Ysebaert L; Dartigeas C; Truchan Graczyk M; Vilque JP; Aurran T; Cymbalista F; Lepretre S; Lévy V; Nguyen-Khac F; Le Garff-Tavernier M; Aanei C; Ticchioni M; Letestu R; Feugier P
    Lancet Haematol; 2019 Sep; 6(9):e470-e479. PubMed ID: 31324600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL.
    Johnson S; Smith AG; Löffler H; Osby E; Juliusson G; Emmerich B; Wyld PJ; Hiddemann W
    Lancet; 1996 May; 347(9013):1432-8. PubMed ID: 8676625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fludarabine may induce durable remission in patients with leptomeningeal involvement of chronic lymphocytic leukemia.
    Knop S; Herrlinger U; Ernemann U; Kanz L; Hebart H
    Leuk Lymphoma; 2005 Nov; 46(11):1593-8. PubMed ID: 16236614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral fludarabine treatment of cutaneous infiltration in a patient with B-cell chronic lymphocytic leukaemia.
    Ural AU; Kubar A; Avcu F; Tastan HB; Safali M; Nevruz O; Cetin T
    Clin Exp Dermatol; 2007 Mar; 32(2):151-4. PubMed ID: 17244344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.
    Farooqui MZ; Valdez J; Martyr S; Aue G; Saba N; Niemann CU; Herman SE; Tian X; Marti G; Soto S; Hughes TE; Jones J; Lipsky A; Pittaluga S; Stetler-Stevenson M; Yuan C; Lee YS; Pedersen LB; Geisler CH; Calvo KR; Arthur DC; Maric I; Childs R; Young NS; Wiestner A
    Lancet Oncol; 2015 Feb; 16(2):169-76. PubMed ID: 25555420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy.
    Weiss MA; Glenn M; Maslak P; Rahman Z; Noy A; Zelenetz A; Scheinberg DA; Golde DW
    Leukemia; 2000 Sep; 14(9):1577-82. PubMed ID: 10995003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
    Rai KR; Peterson BL; Appelbaum FR; Kolitz J; Elias L; Shepherd L; Hines J; Threatte GA; Larson RA; Cheson BD; Schiffer CA
    N Engl J Med; 2000 Dec; 343(24):1750-7. PubMed ID: 11114313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia.
    Thompson PA; O'Brien SM; Xiao L; Wang X; Burger JA; Jain N; Ferrajoli A; Estrov Z; Keating MJ; Wierda WG
    Cancer; 2016 Feb; 122(4):565-73. PubMed ID: 26588193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ibrutinib and rituximab for chronic lymphocytic leukaemia.
    Stirrups R
    Lancet Oncol; 2019 Sep; 20(9):e471. PubMed ID: 31402323
    [No Abstract]   [Full Text] [Related]  

  • 12. Central nervous system involvement of previously undiagnosed chronic lymphocytic leukemia in a patient with neuroborreliosis.
    Kalac M; Suvic-Krizanic V; Ostojic S; Kardum-Skelin I; Barsic B; Jaksica B
    Int J Hematol; 2007 May; 85(4):323-5. PubMed ID: 17483076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor.
    Rogers KA; Huang Y; Ruppert AS; Salem G; Stephens DM; Heerema NA; Andritsos LA; Awan FT; Byrd JC; Flynn JM; Maddocks KJ; Jones JA
    Br J Haematol; 2018 Jan; 180(2):259-266. PubMed ID: 29193006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.
    Cuneo A; Follows G; Rigolin GM; Piciocchi A; Tedeschi A; Trentin L; Perez AM; Coscia M; Laurenti L; Musuraca G; Farina L; Delgado AR; Orlandi EM; Galieni P; Mauro FR; Visco C; Amendola A; Billio A; Marasca R; Chiarenza A; Meneghini V; Ilariucci F; Marchetti M; Molica S; Re F; Gaidano G; Gonzalez M; Forconi F; Ciolli S; Cortelezzi A; Montillo M; Smolej L; Schuh A; Eyre TA; Kennedy B; Bowles KM; Vignetti M; de la Serna J; Moreno C; Foà R; Ghia P;
    Haematologica; 2018 Jul; 103(7):1209-1217. PubMed ID: 29674504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial.
    Elter T; Gercheva-Kyuchukova L; Pylylpenko H; Robak T; Jaksic B; Rekhtman G; Kyrcz-Krzemień S; Vatutin M; Wu J; Sirard C; Hallek M; Engert A
    Lancet Oncol; 2011 Dec; 12(13):1204-13. PubMed ID: 21992852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials.
    Jones J; Mato A; Coutre S; Byrd JC; Furman RR; Hillmen P; Osterborg A; Tam C; Stilgenbauer S; Wierda WG; Heerema NA; Eckert K; Clow F; Zhou C; Chu AD; James DF; O'Brien SM
    Br J Haematol; 2018 Aug; 182(4):504-512. PubMed ID: 29873072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.
    O'Brien S; Jones JA; Coutre SE; Mato AR; Hillmen P; Tam C; Österborg A; Siddiqi T; Thirman MJ; Furman RR; Ilhan O; Keating MJ; Call TG; Brown JR; Stevens-Brogan M; Li Y; Clow F; James DF; Chu AD; Hallek M; Stilgenbauer S
    Lancet Oncol; 2016 Oct; 17(10):1409-1418. PubMed ID: 27637985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Experience with fludarabine treatment and review of the literature].
    Telek B; Rejtó L; Kiss A; Batár P; Reményi G; Rák K; Udvardy M
    Orv Hetil; 2002 Jun; 143(24):1459-65. PubMed ID: 12138643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia.
    Salles G; Bachy E; Smolej L; Simkovic M; Baseggio L; Panovska A; Besson H; Healy N; Garside J; Iraqi W; Diels J; Pick-Lauer C; Spacek M; Urbanova R; Lysak D; Hermans R; Lundbom J; Callet-Bauchu E; Doubek M
    Ann Hematol; 2019 Dec; 98(12):2749-2760. PubMed ID: 31745601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.
    Moreno C; Greil R; Demirkan F; Tedeschi A; Anz B; Larratt L; Simkovic M; Samoilova O; Novak J; Ben-Yehuda D; Strugov V; Gill D; Gribben JG; Hsu E; Lih CJ; Zhou C; Clow F; James DF; Styles L; Flinn IW
    Lancet Oncol; 2019 Jan; 20(1):43-56. PubMed ID: 30522969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.